GHRP-6: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข4 clinical studies cited
- โขOverall evidence level: moderate
- โข5 research gaps identified
Research Studies
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone
Bowers CY, Reynolds GA, Durham D, et al. (1990) โข Journal of Clinical Endocrinology and Metabolism
Foundational study demonstrating GHRP-6 stimulates GH release in normal men and acts synergistically with GHRH, establishing the basic pharmacology of growth hormone secretagogues.
Key Findings
- GHRP-6 stimulates dose-dependent GH release in normal men
- Synergistic GH response when combined with GHRH
- GH response occurs within 15-30 minutes
Limitations: Small number of subjects; single-dose study
Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging
Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML (1997) โข Recent Progress in Hormone Research
Comprehensive review covering GHRP discovery, GHS receptor cloning, and therapeutic potential of growth hormone secretagogues including in aging.
Key Findings
- GHRP discovered in 1981; receptor subsequently cloned
- Oral GH secretagogues (MK-677) stimulate physiologic GH patterns
- GH secretagogues show promise for treating age-related GH decline
Limitations: Review article; MK-677 focus rather than GHRP-6 specifically
Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction
Berlanga J, Cibrian D, Guevara L, et al. (2007) โข Clinical Science
Preclinical study demonstrating GHRP-6 reduces myocardial infarct size by 78% in a porcine model through preservation of antioxidant defense systems.
Key Findings
- GHRP-6 reduced infarct size by 78% in porcine model
- Preserved antioxidant defense systems
- Decreased reactive oxygen species
Limitations: Porcine model; applicability to human cardiac protection uncertain
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood
Micic D, Popovic V, Kendereski A, Macut D, Casanueva FF, Dieguez C (1995) โข Clinical Endocrinology
Study comparing GH responses to GHRP-6 in young and older adults, showing that GHRP-6-stimulated GH release is maintained in late adulthood.
Key Findings
- GH responses to GHRP-6 were not significantly different between young and old
- Combined GHRP-6 + GHRH maintained full response in older subjects
- Impaired GH secretion in aging is a functional and potentially reversible state
Limitations: Cross-sectional design; small sample size
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 100+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขLong-term safety and efficacy of chronic GHRP-6 administration in humans
- โขOptimal dosing protocols for different therapeutic indications
- โขMechanism of cardioprotective effects independent of GH release
- โขWhether GHRP-6 cardiovascular benefits translate to clinical outcomes
- โขHead-to-head comparisons with other GHS peptides in controlled trials
Research Overview#
GHRP-6 research spans over three decades, from its development as one of the first synthetic growth hormone secretagogues through to its use as a pharmacological tool for studying the GH axis and exploration of its non-GH-related biological activities, particularly cardioprotection and cytoprotection.
Growth Hormone Secretion Studies#
Foundational Pharmacology#
The pioneering work of Cyril Bowers and colleagues established GHRP-6 as a potent stimulus for GH release in humans. In their 1990 study, intravenous administration of GHRP-6 (1 mcg/kg) to normal men produced significant increases in serum GH levels, with peak responses occurring at approximately 15-30 minutes. A critical finding was the synergistic interaction between GHRP-6 and GHRH: when the two peptides were co-administered, the resulting GH release was substantially greater than the sum of their individual effects.
This synergism has practical implications: it suggests that GHRP-6 and GHRH act through complementary mechanisms. GHRH directly stimulates GH gene transcription and release, while GHRP-6 amplifies this effect through GHS-R1a-mediated signaling and through suppression of somatostatin tone. The combination approach has been explored as a diagnostic test for GH deficiency and as a therapeutic strategy.
Age-Related Decline#
The study by Arvat and colleagues demonstrated that GH responses to GHRP-6 decline with age, mirroring the well-known age-related decrease in GH secretion (somatopause). However, even elderly subjects retained a significant response to GHRP-6, suggesting that the somatotroph cells remain capable of responding to GHS-R1a stimulation even when basal GH secretion has declined. The combination of GHRP-6 with GHRH partially overcame the age-related attenuation, supporting the concept that the reduction in GH secretion with aging involves both decreased GHRH drive and increased somatostatin tone.
Dose-Response Relationships#
Multiple studies have characterized the dose-response relationship for GHRP-6-stimulated GH release:
- Intravenous: 0.1-1.0 mcg/kg produces significant GH release; maximal responses at approximately 1-2 mcg/kg
- Subcutaneous: 1-2 mcg/kg produces reliable GH peaks
- Intranasal: Higher doses required (10-30 mcg/kg) due to lower bioavailability
The GH response to GHRP-6 shows partial desensitization with repeated administration, though significant GH-releasing activity is maintained even with chronic dosing.
Cardioprotective Research#
Cardiac Effects in Humans#
Broglio and colleagues demonstrated that GHRP-6 has acute positive effects on cardiac function in healthy humans, including increases in cardiac output and left ventricular ejection fraction. These effects appeared to be at least partially independent of the accompanying GH release, suggesting direct cardiac actions of GHRP-6, possibly mediated by cardiac GHS-R1a receptors or the related receptor CD36.
Ischemia-Reperfusion Protection#
A series of preclinical studies, particularly from Cuban research groups led by Berlanga and colleagues, demonstrated significant cardioprotective effects of GHRP-6 in rat ischemia-reperfusion models. GHRP-6 pre-treatment reduced infarct size, decreased markers of oxidative stress, and inhibited apoptosis in cardiomyocytes. The proposed mechanisms include activation of anti-apoptotic signaling pathways (PI3K/Akt), reduction of reactive oxygen species production, and modulation of inflammatory responses.
These cardiac protective effects have also been demonstrated in hepatic ischemia-reperfusion injury, suggesting a broader cytoprotective mechanism rather than tissue-specific effects.
GHS-R1a Receptor Biology#
GHRP-6 has been an invaluable tool for studying GHS-R1a receptor biology. Key findings facilitated by GHRP-6 research include:
- Receptor identification: GHRP-6 binding studies contributed to the identification and cloning of the GHS-R1a receptor
- Constitutive activity: The discovery that GHS-R1a has high constitutive activity was partly enabled by GHRP-6 pharmacological studies
- Appetite regulation: GHRP-6's orexigenic effects paralleled the discovery of ghrelin as the endogenous GHS-R1a ligand
Appetite and Metabolic Studies#
GHRP-6's activation of GHS-R1a produces a significant increase in appetite, mimicking the orexigenic effects of ghrelin. This side effect, while undesirable for some research applications, has made GHRP-6 useful for studying the hypothalamic circuits controlling feeding behavior. The appetite stimulation is more pronounced with GHRP-6 than with some other GHS peptides (particularly ipamorelin), which may relate to differences in receptor subtype selectivity or downstream signaling preferences.
Evidence Quality Assessment#
The evidence base for GHRP-6 is moderate to strong for its GH-releasing effects, with consistent findings across multiple human studies and dose ranges. The cardioprotective evidence is promising but largely preclinical, with limited human data. The overall evidence level is rated moderate, reflecting robust pharmacological characterization but limited long-term clinical outcome data.
Related Reading#
Where to Find GHRP-6
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About GHRP-6
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.